ST. LOUIS (April 17, 2013) — BioGenerator recently led syndication of investment in Adarza BioSystems, Inc., to support further commercialization of the company’s immunoassay products. As part of the investment, Adarza will conduct its primary business and product development in St. Louis as well as its manufacturing activities.
Adarza is a next-generation multiplex immunoassay product company focused on applications in life science tools and the in vitro diagnostics markets. Multiplex technology allows researchers to explore the regulation of many different targets simultaneously. Adarza’s products and services utilize its proprietary Arrayed Imaging Reflectometry™ (“AIR”) detection platform that is capable of rapid identification and quantification and offers key performance benefits in multiplexing, sensitivity, speed, sample size, dynamic range, and ease of use while affording industry-leading low cost. The AIR platform addresses many commercial applications, including disease biomarkers, personalized medicine, drug and vaccine development, allergy, immunology, and infectious diseases research.
“Adarza’s product platform represents an exciting advance in the rapidly growing fields of proteomics and high content biology,” said Charlie Bolten, Vice President of the BioGenerator. “We are excited by the commercial demand for this technology.”
“Adarza has made significant progress with advancing its proprietary Arrayed Imaging Reflectometry™ immunoassay technology and is looking forward to establishing the next level of product development and manufacturing in St. Louis this year,” said Rand Henke, CEO of Adarza BioSystems. “We believe the St. Louis life science research and industry community and its vibrant entrepreneurial infrastructure offer Adarza a dynamic environment for growth and success.” “St. Louis is fortunate to have a deep talent pool for developing and assembling assays and diagnostic products,” said Dr. Eric Gulve, President of BioGenerator. “We are pleased that the availability of talent and St. Louis’ network of support for bioscience companies attracted Adarza to St. Louis and are excited to help advance Adarza’s growth.”
Adarza BioSystems received investment from the St. Louis Arch Angels and other private investors in addition to the investment made by the BioGenerator. The company will initially locate in the Center for Emerging Technologies. Adarza represents the second out-of-state company in the last three months to establish operations in St. Louis following an investment from the BioGenerator.
About BioSTL
BioSTL is a nonprofit that builds regional capacity and fosters collaborative efforts to advance innovation, entrepreneurship, and new company creation that capitalize on St. Louis’ world-class medical and plant biosciences and to promote economic growth and regional prosperity in St. Louis. Please visit www.biostl.org for additional information. Twitter: @BioSTL. Facebook: BioSTL.
About BioGenerator
The BioGenerator, the non-profit venture development organization of BioSTL, facilitates the formation of successful, sustainable bioscience companies in the St. Louis region. It provides start-up bioscience companies with pre-seed and seed investment funds, shared lab space with specialized equipment, and in-depth management support. Please visit www.biogenerator.org for additional information. Twitter: @BioGeneratorSTL.
Contact:
Kamyla Tomiser
BioGenerator
Office: (314) 615-6355
ktomiser@biogenerator.org
